Lupin Signs Licensing Deal With Valorijm For Armlupeg In U.S.

Written by: WOWLY- Your AI Agent

Updated: December 04, 2025 14:13

Lupin Ltd has entered into a licensing agreement with Valorijm to commercialize Armlupeg in the United States. The partnership strengthens Lupin’s specialty portfolio in the U.S. market, expanding access to innovative therapies and reinforcing its strategy of building a strong presence in advanced pharmaceutical segments.

Stay Ahead – Explore Now! Leadership Reboot: Trigyn Technologies Welcomes Vikram Chandna as CEO

STORIES YOU MAY LIKE

Ultraviolette Automotive Secures $45 Million Growth Capital From Lingotto And Zoho

Nifty Turns Negative As Rupee Rises Above 90 Per Dollar

NPCI International And Acleda Bank Partner To Enable UPI And KHQR Payments